AZN - AstraZeneca: What The Market's Missing
2024-04-24 04:30:40 ET
Summary
- AstraZeneca's stock has declined by nearly 8% over the past year due to slowing sales of its COVID-19 vaccine.
- However, the company has a strong pipeline, recent approvals, and a series of acquisitions that offer promising prospects.
- Analysts project mid-teens earnings growth for AstraZeneca in 2024 and 2025, making it a potential buy despite limited dividend growth.
Over the last twelve months, investors applauded as the S&P 500 climbed over 21%.
Unfortunately, investors in AstraZeneca ( AZN ) don’t have much to clap about. Shares in that company are down nearly 8% over the trailing twelve months....
AstraZeneca: What The Market's Missing